Date: 30 March 2022
Swissmedic, Swiss Agency for Therapeutic Products

Swiss Public Assessment Report

Extension of therapeutic indication

TRIKAFTA

International non-proprietary name: elexacaftor, ivacaftor, tezacaftor

Pharmaceutical form: film-coated tablet

Dosage strength:

Morning dose:

50 mg of elexacaftor, 25 mg of tezacaftor, and 37.5 mg of ivacaftor as a fixed-dose combination tablet

100 mg of elexacaftor, 50 mg of tezacaftor, and 75 mg of ivacaftor as a fixed-dose combination tablet

Evening dose:

75 mg, 150 mg of ivacaftor

Route(s) of administration: oral

Marketing Authorisation Holder: Vertex Pharmaceuticals (CH) GmbH

Marketing Authorisation No.: 67773

Decision and Decision date: extension of indication
approved on 5 January 2022

Note:

Assessment Report as adopted by Swissmedic with all information of a commercially confidential nature deleted.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

About Swissmedic

Swissmedic is the Swiss authority responsible for the authorisation and supervision of therapeutic products. Swissmedic's activities are based on the Federal Act of 15 December 2000 (Status as of 1 January 2020) on Medicinal Products and Medical Devices (TPA, SR 812.21). The agency ensures that only high-quality, safe and effective drugs are available in Switzerland, thus making an important contribution to the protection of human health.

About the Swiss Public Assessment Report (SwissPAR)

- The SwissPAR is referred to in Article 67 para. 1 of the Therapeutic Products Act and the implementing provisions of Art. 68 para. 1 let. e of the Ordinance of 21 September 2018 on Therapeutic Products (TPO, SR 812.212.21).
- The SwissPAR provides information about the evaluation of a prescription medicine and the considerations that led Swissmedic to approve or not approve a prescription medicine submission. The report focuses on the transparent presentation of the benefit-risk profile of the medicinal product.
- A SwissPAR is produced for all human medicinal products with a new active substance and transplant products for which a decision to approve or reject an authorisation application has been issued.
- A supplementary report will be published for approved or rejected applications for an additional indication for a human medicinal product for which a SwissPAR has been published following the initial authorisation.
- The SwissPAR is written by Swissmedic and is published on the Swissmedic website. Information from the application documentation is not published if publication would disclose commercial or manufacturing secrets.
- The SwissPAR is a “final” document, which provides information relating to a submission at a particular point in time and will not be updated after publication.
- In addition to the actual SwissPAR, a concise version of the SwissPAR that is more comprehensible to lay persons (Public Summary SwissPAR) is also published.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

Table of contents

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

1 Terms, Definitions, Abbreviations

ADA	Anti-drug antibody
ADME	Absorption, Distribution, Metabolism, Elimination
AE	Adverse events
ALT	Alanine aminotransferase
API	Active pharmaceutical ingredient
ATC	Anatomical Therapeutic Chemical Classification System
AUC	Area under the plasma concentration-time curve
AUC0-24h	Area under the plasma concentration-time curve for the 24-hour dosing interval
BMI	Body mass index
CF	Cystic fibrosis
CFQ-R	Cystic Fibrosis Questionnaire-Revised
CFTR	Cystic fibrosis transmembrane conductance regulator
Cmax	Maximum observed plasma/serum concentration of drug
CYP	Cytochrome P450
ERA	Environmental Risk Assessment
ELX	Elexacaftor
FAS	Full Analysis Set
FEV1	Forced expiratory volume in 1 second
GGT	Gamma-glutamyl transferase
GLP	Good Laboratory Practice
ICH	International Council for Harmonisation
Ig	Immunoglobulin
INN	International Nonproprietary Name
IVA	Ivacaftor
LCI2.5	Number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value
LoQ	List of Questions
LS	Least squares
MAH	Marketing Authorisation Holder
Max	Maximum
Min	Minimum
N/A	Not applicable
NO(A)EL	No Observed (Adverse) Effect Level
PD	Pharmacodynamics
PIP	Paediatric Investigation Plan (EMA)
PK	Pharmacokinetics
ppFEV1	Percent predicted FEV1
PopPK	Population PK
PSP	Pediatric Study Plan (US-FDA)
RD	Respiratory domain
RMP	Risk Management Plan
SD	Standard deviation
SwissPAR	Swiss Public Assessment Report
TE	Treatment-emergent
TEZ	Tezacaftor
TPA	Federal Act of 15 December 2000 (Status as of 1 January 2020 on Medicinal Products and Medical Devices (SR 812.21)
TPO	Ordinance of 21 September 2018 (Status as of 1 April 2020) on Therapeutic Products (SR 812.212.21)
ULN	Upper limit of normal
YOA	Years of age

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

2 Background Information on the Procedure

2.1 Applicant's Request(s)

Fast-track authorisation procedure (FTP)
The applicant requested a fast-track authorisation procedure in accordance with Article 7 of the TPO.

Orphan drug status
The applicant requested Orphan Drug Status in accordance with Article 4 adecies no. 1 of the TPA. The Orphan Status was granted on 9 April 2020.

Extension(s) of the therapeutic indication(s)
The applicant requested to add or change the indication in accordance with Article 23 TPO.
This indication requires the use of a new dosage strength of the medicinal product. The applicant requested the authorisation of this new dosage strength according to Article 24 TPO.

2.2 Indication and Dosage

2.2.1 Requested Indication

Trikafta is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one *F508del* mutation in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene (see «Clinical efficacy»).

2.2.2 Approved Indication

Trikafta is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one *F508del* mutation in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene (see «Clinical efficacy»).

2.2.3 Requested Dosage

Dosing recommendation for patients aged 6 years and older		
Age	**Morning Dose**	**Evening Dose**
6 to <12 years weighing <30 kg	Two tablets, each containing elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg	One tablet containing ivacaftor 75 mg
6 to <12 years weighing ≥30 kg	Two tablets, each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg	One tablet containing ivacaftor 150 mg
≥12 years	Two tablets, each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg	One tablet containing ivacaftor 150 mg

The morning and evening doses should be taken approximately 12 hours apart, with fat-containing food.

2.2.4 Approved Dosage

(see appendix)

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

2.3 Regulatory History (Milestones)

Application	30 April 2021
Formal control completed	4 May 2021
List of Questions (LoQ)	8 July 2021
Answers to LoQ	5 September 2021
Predecision	19 October 2021
Answers to Predecision	16 December 2021
Final Decision	5 January 2021
Decision	approval

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

3 Medical Context

Cystic Fibrosis

Cystic fibrosis (CF) is a genetic disease caused by a deficiency and/or dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR). The CFTR protein is a pore-forming transmembrane protein and functions as a cAMP-regulated chloride channel. The gene has several mutations/defects, which to some extent can be found simultaneously in the same patient. More than 2,000 mutations of the gene have been identified, although only about 10% of those are definitely disease-causing. Heterozygous gene carriers are healthy (prevalence in Central Europe approx. 1:25). This leads to different degrees of severity of disease – from virtually no clinical manifestations to severely hampered lung function and multi-organ manifestation. In some cases, the symptoms may not appear until after childhood and often manifest as pancreatitis, sinusitis, nasal polyps, diffuse bronchiectasis and/or male infertility. Today, the diagnosis of CF is based on typical clinical symptoms and laboratory confirmation of the underlying dysfunction of the CFTR protein. Measuring of chloride concentration in sweat by quantitative pilocarpine iontophoresis represents the gold standard of diagnosis of CFTR dysfunction. Due to the achievements of modern diagnostics and therapy, almost all patients reach adulthood in industrialised countries today. Half of all people living with CF in Switzerland are older than 17 years. The median age of survival in 2012 was between 40 and 50 years in various industrialised countries.

The most common defect is the lack of coding for phenylalanine (F508del), which leads to a processing disorder and therefore to an obstacle in the transport of CFTR to the cell surface. Approximately 45% of patients with cystic fibrosis have a homozygous defect in this allele, which leads to an extensive CFTR malfunction and therefore to severe forms of disease. In addition, there are a number of other mutations that impair CFTR function in various ways and to varying extents.

Current therapeutic options and importance of the requested combination

In addition to a number of symptomatic treatments (e.g. dornase alpha, inhaled antibiotics), the following CFTR potentiators have been available for a few years. These were initially approved for defined gating mutations (class III), homozygous F508del mutations and heterozygous F508del with residual function mutations in the second CFTR gene.

Ivacaftor (IVA): In the presence of cAMP, ivacaftor *in vitro* improves the chloride transport capacity of CFTR (by potentiating the channel-open probability or gating) in both wild-type and various mutations, the extent of this being dependent on the mutation. In order for ivacaftor to have an effect, CFTR proteins must be present on the cell surface. The compound is approved for some defined gating mutations (class III) in the CFTR gene. Clinical studies with ivacaftor show an improvement in the sweat test by about 50 mmol/l, stabilisation of the clinical condition as well as an increase in FEV1 (forced expiratory volume in 1 second) by about 10%.

Lumacaftor is used only in combination with IVA: chaperone protein, which influences the folding of CFTR and in so doing improves the stability of the conformation and transport to the surface. The combination lumacaftor/IVA is approved for homozygous F508del mutations in the CFTR gene.

Tezacaftor (TEZ) is used only in combination with IVA. Tezacaftor *in vitro* improves the processing and transport of normal CFTR and certain mutations, and in so doing leads to an increase in mature surface CFTR. The combination TEZ/IVA is approved for homozygous F508del mutations and heterozygous F508del mutations in combination with certain “residual function” mutations in the second CFTR gene.

Elexacaftor (ELX) is used for treatment in combination with TEZ and IVA as Trikafta (ELX/TEZ/IVA). ELX *in vitro* improves the processing and transport of normal CFTR in certain mutations but binds to other areas of the CFTR protein than TEZ. With the combination ELX/TEZ/IVA, a functional improvement for F508del mutations is achieved, which is more pronounced than with TEZ/IVA. It is beneficial, even in the case of heterozygous F508del mutations with complete and therapy-resistant malfunction of the second CFTR gene (minimal function mutation).

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

4 Quality Aspects

4.1 Drug Product

Description and Composition:
Elexacaftor 50 mg / tezacaftor 25 mg / ivacaftor 37.5 mg tablet is a new dosage strength of the elexacaftor 100 mg / tezacaftor 50 mg / ivacaftor 70 mg tablet. It is a light orange capsule-shaped film coated tablet, debossed with “T50” on one face and plain on the other face. The new elexacaftor 50 mg / tezacaftor 25 mg / ivacaftor 37.5 mg tablet core is a weight multiple of the authorised tablet. The same film coating components are used.
Ivacaftor 75 mg tablet is a new dosage strength of the Ivacaftor 150 mg tablet. It is a light blue capsule-shaped tablet printed with “V 75” in black ink on one face and plain on the other. The new Ivacaftor 75 mg tablet core is a weight multiple of the authorised tablet. The same film coating components are used.

Pharmaceutical Development:
Suitable pharmaceutical development data have been provided for the finished product composition and manufacturing process, including a QbD (Quality by Design) approach.

Manufacture:
The manufacturing processes are sufficiently described. Adequate in-process controls are established in order to ensure a consistent manufacturing process.

Specification:
The drug product specifications cover relevant physicochemical characteristics as well as identification, assay and purity tests. The analytical procedures are validated according to the recommendations of international guidelines.

Container Closure System:
The container closure system is a thermoform blister consisting of clear Aclar (PCTFE – polychlorotrifluoroethylene) film laminated to PVC (polyvinyl chloride) film and sealed with a blister foil lidding.

Stability:
Appropriate stability data have been generated in the packaging material intended for commercial use and following the relevant international guidelines. The data show good stability of the finished product and allow for a distinct assignment of the shelf life.

4.2 Quality Conclusions

Satisfactory and consistent quality of the drug product has been demonstrated.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

5 Nonclinical Aspects

The applicant did not submit any new nonclinical studies to support the addition of a new dosage strength elexacaftor 50 mg / tezacaftor 25 mg / ivacaftor 37.5 mg and ivacaftor 75 mg film-coated tablets (combination package) and the requested extension of the indication. This was considered acceptable since there are no changes with regard to posology and method of administration.

The applicant was requested to submit the updated ERA for elexacaftor following finalisation of the Phase II studies (post-approval commitment).

From the nonclinical point of view, there are no objections to approval of the proposed new dosage strength and extension of indication.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

6 Clinical and Clinical Pharmacology Aspects

6.1 Clinical Pharmacology

Bioanalytical methodology: For the determination of ELX, M23-ELX, TEZ, M1-TEZ, IVA and M1-IVA, previously validated and submitted bioanalytical methods were employed in studies #011 and #106. In addition, bioanalytical reports were submitted for both studies indicating acceptable performance during sample analysis derived from the subjects of studies #011 and #106.

Biopharmaceutical development: The applicant proposes a new triple combination tablet for ELX/TEZ/IVA at a strength of 50 mg / 25 mg / 37.5 mg. The tablet is a light orange, immediate-release, film-coated tablet. The proposed triple combination tablet for ELX/TEZ/IVA at a strength of 50 mg / 25 mg / 37.5 mg is proportional to the approved triple combination tablet for ELX/TEZ/IVA at a strength of 100 mg / 50 mg / 75 mg.

In addition, a new single-component tablet for IVA with a strength of 75 mg is proposed. The tablet is a light blue, immediate-release, film-coated tablet. The proposed 75-mg tablet is proportional in composition to the approved 150-mg tablet.

The applicant submitted PK data from 2 studies: **# 011** and **# 106** (Part A and Part B).

Study #011 demonstrated bioequivalence of a single dose of 2 tablets of the proposed triple combination of ELX/TEZ/IVA at a strength of 50 mg / 25 mg / 37.5 mg to 1 tablet of the approved triple combination of ELX/TEZ/IVA at a strength of 100 mg / 50 mg / 75 mg in healthy adult subjects. The standard bioequivalence acceptance criteria were met for C_{max} and AUC for all three analytes since all calculated 90% confidence intervals were fully contained within the limits of 80–125%.

Study #106 was conducted in patients 6 through 11 years of age in two parts. **Part A** investigated a dose level that was selected based on popPK modelling developed on data from subjects ≥18 years of age with the intention of achieving the target exposures observed previously to be safe and effective in subjects ≥18 years of age. Using the PK results from Part A, the **Part B** doses and weight cut-off were selected. Following the completion of Part B, the existing popPK databases were updated with PK data from Part B for the final popPK analyses. The resulting exposures in the age group 6 through 11 years with a weight < 30 kg receiving half the adult doses appear in the desired range, whereas in the weight group ≥ 30 kg, the proposed adult doses result in exposure above or at the upper end of the targeted exposure range.

6.2 Dose Finding and Dose Recommendation

There was no classical dose-finding study.

Protocol VX18-445-106 was a Phase III clinical study with two parts: A, B. Part A was used for PK sampling with an assumed standard dose (half the dose of patients ≥12 years of age (YOA)), and the pivotal dosing for Part B was calculated afterwards in separate popPK models (see above). Protocol VX18-445-106 Part A could be seen as a supplemental dose-finding study.

Protocol VX18-445-106 Part A examined 16 children with CF 6 – 11 YOA with F508del homozygotes (F/F, n=7, 43.8%) and F508del/MF heterozygotes (F/MF, n=9, 56.3%) with Trikafta over 15 days of treatment and 28 days of safety follow-up afterwards. Mean age was 9.0 years, 68.8% (n=11) were female, 31.3% (n=5) were male, mean baseline ppFEV1 was near normal at 85.1% (80%-120% normal) and mean baseline sweat-chloride was highly elevated at 104.1 mmol/L (>60 mmol/L = definitive CF). Patients with G6PD deficiency were excluded. All 16 subjects (100%) were completers.

All subjects in Protocol VX18-445-106 Part A, regardless of bodyweight, were treated **with half the standard dose** of CF patients ≥12 YOA: 100 mg ELX once daily, 50 mg TEZ once daily, 75 mg IVA twice daily together with a fat-containing snack/meal. Efficacy was not an objective of Part A.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

Descriptive statistics were done on spirometry, sweat chloride, weight, height and body mass index (BMI). However, because of the short treatment and missing objectives regarding efficacy, these efficacy results are hardly relevant for dose finding. Nevertheless, there was a relevant improvement in ppFEV1 within 15 days of 11.8 (8.9) percentage points and in sweat-chloride of -50.9 (13.1) mmol/L. Conduct of Part A was not impacted by the COVID-19 pandemic.

The final dose regimen chosen for Protocol VX18-445-106 Part B (see below) was based on a popPK model indicating this regimen would result in ELX, TEZ and IVA exposures similar to exposures in subjects ≥18 years.

The results in Part A regarding dose finding could be accepted from a clinical point of view for the chosen dosage in Part B (details see pop-PK).

Protocol VX18-445-106 Part B also collected PK samples. These were integrated into the pop-PK model (see Pharmacokinetics above). Exposure of the active metabolite M1-TEZ in weight group ≥30 kg was higher than in patients ≥12 YOA. This higher exposure of M1-TEZ could be a safety relevant issue (liver toxicity).

6.3 Efficacy

Pivotal study – Protocol VX18-445-106 Part B

Study Design

Protocol VX18-445-106 Part B was an open uncontrolled Phase III study with Trikafta in 66 children with CF 6 – 11 years of age (YOA). There were F508del homozygotes (F/F, n=29, 43.9%) and F508del/MF heterozygotes (F/MF, n=37, 56.1%). The disease intensity of CF was severe, the minimum weight was ≥15 kg (15 kg = lower than the 3rd percentile of normal range). There were 40.9% (n=27) males and 59.1% (n=39) females. Mean age was 9.3 years (min 6.1, max 12.1 years); median age was 9.6 years. Patients with liver cirrhosis, of transaminases ≥3 ULN, bilirubin ≥2 ULN and renal failure (GF ≤45 mL/min/1.73 m^2) were excluded. Moderate and strong CYP3A inducers and CYP3A inhibitors (except ciprofloxacin) were prohibited. Special attention was given to signs of liver toxicity. The possible development of rash including grade 3 and higher was another concern that was closely monitored.

Subjects in Protocol VX18-445-106 Part B **with a bodyweight < 30 kg** were treated **with half the standard dose** of CF patients ≥12 YOA: 100 mg ELX once daily, 50 mg TEZ once daily, 75 mg IVA twice daily together with a fat-containing snack/meal.

Subjects in Protocol VX18-445-106 Part B with a bodyweight **≥30 kg** were treated **with the full standard dose** of CF patients ≥12 YOA: 200 mg ELX once daily, 100 mg TEZ once daily, 150 mg IVA twice daily together with a fat-containing snack/meal.

Study conduct was impacted by the COVID-19 pandemic as described in the information for healthcare professionals. Several assessments were done during home visits instead of at the study sites as planned. A large impact of these changes on the study outcomes is considered unlikely, but an effect cannot not be excluded.

Endpoints and Statistics

There was no primary efficacy endpoint and no control group.

Main secondary endpoints were absolute change from baseline to Week 24 in ppFEV1, absolute change from baseline to Week 24 in sweat-chloride and pulmonary exacerbations up to Week 24, which are accepted endpoints in line with the guideline EMEA/CHMP/EWP/9147/2008-corr*. FEV1 is

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

the most adequate endpoint in adults and children ≥5 YOA with CF. FEV1 is correlated with long-term survival in CF.

There was no correction for multiple testing. The statistical analyses were descriptive.

Power was adequate for detection of an AE incidence of 5% with >92.3% probability, which is considered adequate.

Study Collective

Protocol VX18-445-106 Part B had 66 subjects; 64 subjects (97.0%) completed.

Most of the patients were white (n=58, 87.9%); most came from the US (n=47, 71.2%) or Europe/Australia (n=19, 28.8%). 36 patients (54.5%) weighed less than 30 kg; 30 patients (45.5%) weighed equal to or above 30 kg. Thus, the weight distribution for the two dosages was well balanced.

ppFEV1 categories at baseline were <70% (n=10, 15.2%), ≥70% – ≤90% (n=22, 33.3%), >90% (n=30, 45.5%) and missing (n=4, 6.1%). ppFEV1 at baseline in 62 subjects was mean 88.8% (SD 17.7); median 89.3%; minimum/maximum 39.0 – 127.1%.

Sweat chloride at baseline in 62 subjects was mean 102.2 mmol/L (SD 9.1); median 101.5 mmol/L; minimum/maximum 75.5 – 122.0 mmol/L.

Patients received typical pre-treatments for CF (e.g. dornase alfa 81.8%, n=54; any inhaled hypertonic saline 78.8%, n=52); pre-treatment with CFTR modulators was low (21.2%, n=14). 26 patients (39.4%) had already had *Pseudomonas aeruginosa* infections within 2 years prior to screening.

Protocol deviations were mostly due to the COVID-19 pandemic.

Results Secondary Endpoints – ppFEV1 and Sweat Chloride

MMRM Analysis of Absolute Change from Baseline in ppFEV1 Through to Week 24 (FAS, Part B)

	ELX/TEZ/IVA N = 66
Baseline	
n	62
Mean (SD)	88.8 (17.7)
Absolute change through Week 24	
n	59
LS mean (SE)	10.2 (1.2)
95% CI of LS mean	(7.9, 12.6)
P value	<0.0001

This is a clinically relevant improvement for ppFEV1 in a mixed homozygote/heterozygote collective, which is in a near similar range to that seen in two controlled studies in patients ≥12 YOA (with naturally more advanced CF disease (heterozygote F508del/MF = FEV1 14.3 (12.7; 15.8), study 445-102 or homozygote F508del/F508del = ppFEV1 10.0 (7.4; 12.6), study 445-103). As such a ppFEV1 result as spontaneous improvement in severe CF over 24 weeks is not biologically feasible, regardless of statistical limitations (not a primary endpoint, no control group, no correction for multiple testing, limited measurements due to COVID-19 pandemic), this ppFEV1 result is acceptable for showing proof of efficacy.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

The number of patients for whom ppFEV1 data were available decreased over the 24 weeks due to the COVID-19 pandemic (see information for healthcare professionals). The LS mean absolute change in ppFEV1 from baseline in the 15 residual patients after 24 weeks was 12.8 (95% CI: 8.9, 16.7;). Sensitivity analyses showed similar results. An additional prespecified analysis was performed that included home-assessed spirometry (i.e. spirometry assessed independently by the subjects at home). The MMRM results for the through Week 24 endpoint (clinic and mobile spirometry data together = FEV1 10.7 in 59 patients) were consistent with the main analysis. Nevertheless, even including mobile spirometry data, not all patients had final FEV1 values at Week 24.

Only one discontinuation was due to AE and one other was due to other reasons. Thus, there are no signs that discontinuations were driven by a safety signal.

The **second secondary endpoint was the absolute change in sweat chloride from baseline through to Week 24**, which is the most relevant pharmacodynamic endpoint.

MMRM Analysis of Absolute Change from Baseline in SwCl Through to Week 24 (FAS, Part B)

	ELX/TEZ/IVA N = 66
Baseline	
n	62
Mean (SD)	102.2 (9.1)
Absolute change through Week 24	
n	60
LS mean (SE)	-60.9 (1.4)
95% CI of LS mean	(-63.7, -58.2)
P value	<0.0001

Treatment with Trikafta resulted in within-group improvements (reductions) through to Week 24. The LS mean absolute change in sweat chloride from baseline (n=62) through to Week 24 was -60.9 mmol/L (95% CI: -63.7, -58.2; P<0.0001, n=60). Data showed that the sweat chloride results were hampered due to the COVID-19 pandemic in the same way as the ppFEV1 results. However, additional analysis supported the result of the secondary endpoint reduction in sweat chloride.

6.4 Safety

Safety from Protocol VX18-445-106 Part A and Protocol VX18-445-106 Part B is presented separately, because different dosages were supplied in both parts. Protocol VX18-445-106 Part A had no safety issues. For Protocol VX18-445-106 Part A, see Dose Finding above.

Protocol VX18-445-106 Part B had total exposure of 1,570.4 patient weeks, 32.7 patient years. There were 66 patients in the safety collective. Mean exposure duration was 23.8 weeks (median 24.1 weeks). One patient had exposure ≤15 days, 27 patients (40.9%) were exposed >20 – ≤24 weeks, 38 patients (57.6) were exposed >24 weeks.

Overall, the safety of Trikafta was acceptable. 65 patients (98.5%) had any AE, 16 (24.2%) had AE not related, 16 (24.2%) had unlikely related AE, 29 (43.9%) had possibly related AE, 4 (6.1%) had related AE, 36 (54.5%) had AE with mild intensity, 28 (42.4%) with moderate intensity and 1 (1.5%) with severe intensity. There were no life-threatening AEs, no related serious AEs, no missing cases and no fatal AEs. One AE of erythematous rash led to study drug discontinuation; one AE led to study drug interruption for 1 day, one AE was grade 3/4; one AE was serious (there was a second not unrelated serious case in the extended period after 24 weeks: pancreatitis). Additional unscheduled visits that were conducted after Week 24 to capture safety laboratory testing missed due to the COVID-19 pandemic showed similar results to the main analysis.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

Most of these AEs are typically correlated with complications of CF. There were two exceptions, increased ALT 10.6%, which is also well known in the same range with Symdeko®; thus, a causal relationship with tezacaftor cannot be excluded. The second exception is rash (12.1%).

Adverse events of special interest (AESIs) were defined as AEs of elevated transaminases and AEs of rash.

Rash Events:
Patients with any rash events n=16 (24.2%), rash n=8 (12.1%), erythematous rash n=3 (4.5%), maculo-papular rash n=2 (3.0%), papular rash n=2 (3.0%), skin exfoliation n=1 (1.5%) and urticaria n=1 (1.5%). The over-all rate of 24.2% rash/skin lesions is very high. All rash events were mild or moderate in severity; none was serious. One subject had a rash event that led to treatment discontinuation. All other rashes resolved without treatment discontinuation or interruption. The rash events had a mean (SD) duration of 6.0 (5.5) days, and the mean (SD) time-to-onset of first event was 22.7 (31.3) days.

Elevated Transaminase Events:
Seven (10.6%) subjects had elevated transaminase events. All of the events were mild or moderate in severity. None of the events was serious or led to treatment discontinuation or interruption. The elevated transaminase events had a mean (SD) duration of 15.3 (9.0) days and the mean (SD) time-to-onset of the first event was 52.1 (62.2) days.
The maximum mean (SD) increases in bilirubin were 3.8 (4.5) µmol/L for total bilirubin, 1.5 (1.5) µmol/L for direct bilirubin, and 2.4 (3.4) µmol/L for indirect bilirubin, each at Week 24. As the direct bilirubin was not elevated according table below, there is no suggestion of bilirubin correlated liver injury including liver failure.

6.5 Final Clinical and Clinical Pharmacology Benefit Risk Assessment

Protocol VX18-445-106 Part B examined a typical collective regarding sweat chloride of severely ill patients with CF (F508del homozygote, F508del/MF heterozygote), who were treated with state-of-the-art standard treatments before the study with Trikafta. 39.4% patients had already had Pseudomonas aeruginosa infections as a sign of somewhat advanced CF disease. Overall this is an adequate study population.

In Protocol VX18-445-106 Part B, there was no primary efficacy endpoint and no control group. All efficacy analysis in Protocol VX18-445-106 Part B were concerned secondary endpoints without correction for multiple testing.

Nevertheless, there were typical, reliable and long-term secondary endpoints, which can be accepted for proof of efficacy in CF patients over 24 weeks. In the case of a high magnitude of therapeutic effects in particular, these results cannot be reached by spontaneous improvement in CF. In the guideline EMEA/CHMP/EWP/9147/2008-corr*, the recommended primary endpoint is FEV1 in adults and children ≥5 YOA.

Treatment with Trikafta resulted in clinically relevant within-group improvements from baseline in ppPEV1 and sweat-chloride through to Week 24.

Other endpoints support the efficacy of Trikafta as shown with FEV1 and sweat chloride in 6 – 11 YOA. However, as collection of data including growth parameters and probes was incomplete due to the pandemic, some results are of limited relevance. Without a control group these further secondary endpoints and two exploratory endpoints should not be mentioned in the information for healthcare professionals. Ad hoc subgroup analyses by genotype subgroup were similar for the F/F and F/MF subgroups.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

Protocol VX18-445-106 Part B was influenced by the COVID-19 pandemic and some of the measurements could not be done as originally planned. An additional prespecified analysis was performed that included home-assessed spirometry (i.e. spirometry assessed independently by the subjects at home) that was permitted due to the pandemic. The results were consistent with the main analysis. Nevertheless, even including mobile spirometry data, not all patients had final ppFEV1 values at Week 24. The same is true for sweat chloride and other secondary and exploratory endpoints.

The safety of Trikafta in 6 – 11 YOA was in principle acceptable. There were two relevant issues.

Elevated Transaminase Events:
Seven (10.6%) subjects had elevated transaminase events. All of the events were mild or moderate in severity. None of the events was serious or led to treatment discontinuation or interruption. The elevated transaminase events had a mean (SD) duration of 15.3 (9.0) days, and the mean (SD) time-to-onset of first event was 52.1 (62.2) days. It is possible that there is an association with tezacaftor or its M1-metabolite. The exposures in the age group 6 to 11 years with a weight < 30 kg receiving half the adult doses appear in the desired range, whereas in the weight group ≥30 kg, the proposed adult doses result in M1-metabolite exposure above or at the upper end of the intended exposure range (up to factor 2).

Rash Events:
Patients with any rash events n=16 (24.2%), rash n=8 (12.1%), erythematous rash n=3 (4.5%), maculo-papular rash n=2 (3.0%), papular rash n=2 (3.0%), skin exfoliation n=1 (1.5%), urticaria n=1 (1.5%). The over-all rate of 24.2% rash/skin lesions is very high. Not all cases could be clearly correlated to Trikafta. All rash events were mild or moderate in severity; none was serious. On the other hand there was only one permanent discontinuation of Trikafta; all other cases resolved without treatment discontinuation or interruption.

Overall, Trikafta showed a clinically relevant difference regarding ppFEV1 in 6 – 11 YOA. The LS mean absolute change in ppFEV1 from baseline (n=59) through to Week 24 was 10.2 percentage points (95% CI: 7.9, 12.6; P<0.0001).

Treatment with Trikafta also resulted in within-group improvements regarding sweat chloride through to Week 24.

The quality of data is somewhat hampered due to the COVID-19 pandemic. Not all measurements could be done as originally planned. Nevertheless, the magnitude of first and second secondary improvements justifies the approval of Trikafta for 6 – 11 YOA.

Protocol VX18-445-106 Part A involved short-term treatment over 15 days and was not impacted by the pandemic. Efficacy was only descriptive. Nevertheless, there was a substantial improvement in ppFEV1 within 15 days of 11.8 (8.9) percentage points and the same is true of an improvement of -50.9 (13.1) mmol/L in sweat- chloride.

Similarly to Symdeko, there were some indications of liver toxicity, which may be explained by tezacaftor or the M1-metabolite. Regular controls of transaminases must be performed. Severe liver toxicity was not seen in Protocol VX18-445-106 Part B.

Rash in different forms was seen often (24.2%). However, there was only one case of definitive treatment termination. All other cases were reversible and a close relationship to Trikafta was not clearly shown. Thus, rash is not a limiting point for approval or not.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

As the therapeutic benefit of Trikafta for 6 – 11 YOA regarding ppFEV1 is high and a positive effect on long-term survival of CF patients can be assumed, the light to moderate liver and skin toxicity observed was weighted by Swissmedic as being acceptable given the therapeutic effect.

Future Relevant Data
Data on long-term effectiveness and safety are expected from study VX19-445-107. This study will include 6 YOA and older completers of study VX18-445-106 Part B under the same dose regimen as in in Protocol VX18-445-106 Part B. Results of this study are requested as stipulation.

6.6 Approved Indication and Dosage

See information for healthcare professionals in the Appendix.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

7 Risk Management Plan Summary

The RMP summaries contain information on the medicinal products' safety profiles and explain the measures that are taken in order to further investigate and monitor the risks as well as to prevent or minimise them.
The RMP summaries are published separately on the Swissmedic website. Marketing Authorisation Holders are responsible for the accuracy and correctness of the content of the published RMP summaries. As the RMPs are international documents, their summaries might differ from the content in the information for healthcare professionals / product information approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorisations.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

8 Appendix

8.1 Approved Information for Healthcare Professionals

Please be aware that the following version of the information for healthcare professionals relating to Trikafta was approved with the submission described in the SwissPAR. This information for healthcare professionals may have been updated since the SwissPAR was published.

Please note that the reference document, which is valid and relevant for the effective and safe use of medicinal products in Switzerland, is the information for healthcare professionals approved and authorised by Swissmedic (see www.swissmedicinfo.ch).

Note:
The following information for healthcare professionals has been translated by the MAH. The Authorisation Holder is responsible for the correct translation of the text. Only the information for healthcare professionals approved in one of the official Swiss languages is binding and legally valid.

Swissmedic • Hallerstrasse 7 • 3012 Berne • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected new or serious adverse reactions. See the «Undesirable effects» section for advice on the reporting of adverse reactions.

Trikafta

Composition

Active substances

Morning dose:

Elexacaftor, tezacaftor, ivacaftor

Evening dose:

Ivacaftor

Excipients

Morning dose:

Tablet core:
Hypromellose, hypromellose acetate succinate, sodium lauryl sulfate, croscarmellose sodium, microcrystalline cellulose, magnesium stearate
Tablet film coat:
Hypromellose, hydroxypropyl cellulose, titanium dioxide, talc, iron oxide yellow, iron oxide red
Each 50 mg/25 mg/37.5 mg tablet contains 1.34 mg of sodium.
Each 100 mg/50 mg/75 mg tablet contains 2.68 mg of sodium.

Evening dose:

Tablet core:
Colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate
Tablet film coat:
Carnauba wax, FD&C Blue #2, PEG 3350, polyvinyl alcohol, talc, titanium dioxide
Printing ink:
Ammonium hydroxide, iron oxide black, propylene glycol, shellac
Each 75 mg tablet contains 0.90 mg of sodium and 83.6 mg of lactose monohydrate.
Each 150 mg tablet contains 1.82 mg of sodium and 167.2 mg of lactose monohydrate.

Pharmaceutical form and active substance quantity per unit

Elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg tablet and ivacaftor 75 mg tablet

Morning dose:

Each 50 mg/25 mg/37.5 mg film-coated tablet contains 50 mg of elexacaftor, 25 mg of tezacaftor and 37.5 mg of ivacaftor as a fixed-dose combination tablet.
Light orange, capsule-shaped tablet debossed with «T50» on one side and plain on the other (6.4 mm x 12.2 mm).

Evening dose:

Each 75 mg film-coated tablet contains 75 mg of ivacaftor.

Light blue, capsule-shaped tablet printed with «V 75» in black ink on one side and plain on the other (12.7 mm x 6.8 mm).

Elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg tablet and ivacaftor 150 mg tablet

Morning dose:

Each 100 mg/50 mg/75 mg film-coated tablet contains 100 mg of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor as a fixed-dose combination tablet.
Orange, capsule-shaped tablet debossed with «T100» on one side and plain on the other (7.85 mm x 15.47 mm).

Evening dose:

Each 150 mg film-coated tablet contains 150 mg of ivacaftor.
Light blue, capsule-shaped tablet printed with «V 150» in black ink on one side and plain on the other (16.5 mm x 8.4 mm).

Indications/Uses

Trikafta is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one *F508del* mutation in the cystic fibrosis transmembrane conductance regulator *(CFTR)* gene («Clinical efficacy»).

Dosage/Administration

Trikafta should only be prescribed by physicians with experience in the treatment of CF. If the patient’s genotype is unknown, confirm the presence of at least one *F508del* mutation using a genotyping assay.

Usual dosage

Adults, adolescents and children aged 6 years and older

Table 1: Dosing recommendation for patients aged 6 years and older		
Age	**Morning Dose**	**Evening Dose**
6 to <12 years weighing <30 kg	Two tablets, each containing elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg	One tablet containing ivacaftor 75 mg
6 to <12 years weighing ≥30 kg	Two tablets, each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg	One tablet containing ivacaftor 150 mg
≥12 years	Two tablets, each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg	One tablet containing ivacaftor 150 mg

The morning and evening dose should be taken with fat-containing food, approximately 12 hours apart (see «Mode of administration»).

Delayed Administration

If 6 hours or less have passed since the missed morning or evening dose, the patient should take the missed dose as soon as possible and continue on the original schedule.
If more than 6 hours have passed since:

- the missed **morning** dose, the patient should take the missed dose as soon as possible and should **not** take the evening dose. The next scheduled morning dose should be taken at the usual time.
- the missed **evening** dose, the patient should **not** take the missed dose. The next scheduled morning dose should be taken at the usual time.

Morning and evening doses should not be taken at the same time.

Mode of administration

For oral use. Patients should be instructed to swallow the tablets whole. The tablets should not be chewed, broken, or dissolved before swallowing.
Trikafta should be taken with fat-containing food. Examples of meals or snacks that contain fat are those prepared with butter or oils or those containing eggs, cheeses, nuts, whole milk, or meats (see «Pharmacokinetic»).
Food or drink containing grapefruit should be avoided during treatment with Trikafta (see «Interactions»).

Special dosage instructions

Patients with impaired hepatic function

Treatment of patients with moderate hepatic impairment (Child-Pugh Class B) is not recommended.

Treatment of patients with moderate hepatic impairment should only be considered when there is a clear medical need and the benefits are expected to outweigh the risks.
Studies have not been conducted in patients with severe hepatic impairment (Child-Pugh Class C). Patients with severe hepatic impairment should not be treated with Trikafta.
No dose adjustment is recommended for patients with mild hepatic impairment (Child Pugh Class A) (see «Pharmacokinetics»).

Table 2: Recommendation for use in Patients with Hepatic Impairment

	Mild (Child-Pugh Class A)	**Moderate (Child-Pugh Class B)***	**Severe (Child-Pugh Class C)**
Morning	No dose adjustment (Two elexacaftor/ tezacaftor/ivacaftor tablets)	Use not recommended*	Should not be used
Evening	No dose adjustment (One ivacaftor tablet)	Use not recommended*	Should not be used

*Treatment of patients with moderate hepatic impairment should only be considered when there is a clear medical need and the benefits are expected to outweigh the risks. If used, Trikafta should be used with caution at a reduced dose, as follows: two elexacaftor/ tezacaftor/ivacaftor tablets alternating with one elexacaftor/tezacaftor/ivacaftor tablet taken in the morning, on alternate days. The evening dose of the ivacaftor tablet should not be taken.

Patients with impaired renal function

No dose adjustment is recommended for patients with mild and moderate renal impairment. Caution is recommended for patients with severe renal impairment or end-stage renal disease (see «Pharmacokinetic»).

Concomitant use of CYP3A inhibitors

When co-administered with moderate CYP3A inhibitors (e.g., fluconazole, erythromycin) or strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, and clarithromycin), the dose should be reduced as in Table 3 (see «Warnings and precautions» and «Interactions»).

Table 3: Dosing Schedule for Concomitant Use of Trikafta with Moderate and Strong CYP3A Inhibitors

Moderate CYP3A Inhibitors				
	Day 1	**Day 2**	**Day 3**	**Day 4***
Morning Dose	Two elexacaftor/ tezacaftor/ivacaftor tablets	One ivacaftor tablet	Two elexacaftor/ tezacaftor/ivacaftor tablets	One ivacaftor tablet
Evening Dose^	No dose			
* Continue dosing with two elexacaftor/tezacaftor/ivacaftor tablets and one ivacaftor tablet on alternate days. ^ The evening dose of ivacaftor should not be taken.				
Strong CYP3A Inhibitors				
	Day 1	**Day 2**	**Day 3**	**Day 4#**
Morning Dose	Two elexacaftor/ tezacaftor/ivacaftor tablets	No dose	No dose	Two elexacaftor/tezacaftor/ ivacaftor tablets
Evening Dose^	No dose			
# Continue dosing with two elexacaftor/tezacaftor/ivacaftor tablets twice a week, approximately 3 to 4 days apart. ^ The evening dose of ivacaftor tablet should not be taken.				

Children

The safety and efficacy of Trikafta in children aged less than 6 years have not been established (see «Undesirable effects» and «Properties/Effects»).

Elderly patients

Clinical studies of Trikafta did not include a sufficient number of patients aged 65 years and older to determine whether they respond differently from younger patients.

Contraindications

Hypersensitivity to the active substances or to any of the excipients (see «Composition»).

Warnings and precautions

Effects on liver function tests

Elevated transaminases are common in patients with CF and have been observed in some patients treated with Trikafta. Assessments of transaminases (ALT and AST) are recommended for all patients prior to initiating Trikafta, every 3 months during the first year of treatment, and annually thereafter. For patients with a history of transaminase elevations, more frequent monitoring should be considered. In the event of ALT or AST >5 x the upper limit of normal (ULN), or ALT or AST >3 x ULN

with bilirubin >2 x ULN, dosing should be interrupted, and laboratory tests closely followed until the abnormalities resolve. Following the resolution of transaminase elevations, consider the benefits and risks of resuming treatment (see «Undesirable effects»).

Interactions with medicinal products

CYP3A inducers

Exposure to ivacaftor is significantly decreased and exposures to elexacaftor and tezacaftor are expected to decrease by the concomitant use of CYP3A inducers, potentially resulting in the reduction of Trikafta efficacy; therefore, co-administration with strong CYP3A inducers is not recommended (see «Interactions»).

CYP3A inhibitors

Exposure to elexacaftor, tezacaftor and ivacaftor are increased when co-administered with strong or moderate CYP3A inhibitors. Therefore, the dose of Trikafta should be reduced when used concomitantly with moderate or strong CYP3A inhibitors (see «Interactions» and Table 3 in «Dosage/Administration»).

Cataracts

Cases of non-congenital lens opacities without impact on vision have been reported in pediatric patients treated with ivacaftor-containing regimens. Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation) a possible risk attributable to treatment with ivacaftor cannot be excluded. Baseline and follow-up ophthalmological examinations are recommended in pediatric patients initiating treatment with Trikafta (see «Preclinical data»).

Patients after organ transplantation

Elexacaftor/tezacaftor/ivacaftor has not been studied in CF patients after organ transplantation. Therefore, its use is not recommended in patients with organ transplants. See «Interactions» for information on interactions with cyclosporine or tacrolimus.

Lactose

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per daily dose, that is to say essentially ‘sodium-free’.

Interactions

Pharmacokinetic interactions

Medicinal products affecting the pharmacokinetics of Trikafta

CYP3A inducers

Elexacaftor, tezacaftor and ivacaftor are substrates of CYP3A (ivacaftor is a sensitive substrate of CYP3A). Concomitant use of CYP3A inducers may result in reduced exposures and thus reduced Trikafta efficacy. Co-administration of ivacaftor with rifampin, a strong CYP3A inducer, significantly decreased ivacaftor area under the curve (AUC) by 89%. Elexacaftor and tezacaftor exposures are expected to decrease during co-administration with strong CYP3A inducers; therefore, co-administration of Trikafta with strong CYP3A inducers is not recommended (see «Warnings and precautions»).

Examples of strong CYP3A inducers include:

- rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St. John's wort (*Hypericum perforatum*)

CYP3A inhibitors

Co-administration with itraconazole, a strong CYP3A inhibitor, increased elexacaftor AUC by 2.8 fold and tezacaftor AUC by 4.0- to 4.5-fold. When co-administered with itraconazole and ketoconazole, ivacaftor AUC increased by 15.6-fold and 8.5-fold, respectively. The dose of Trikafta should be reduced when co-administered with strong CYP3A inhibitors (see «Warnings and precautions» and Table 3 in «Dosage/Administration»).

Examples of strong CYP3A inhibitors include:

- ketoconazole, itraconazole, posaconazole, and voriconazole
- telithromycin and clarithromycin

Simulations indicated that co-administration with moderate CYP3A inhibitors may increase elexacaftor and tezacaftor AUC by approximately 1.9 to 2.3-fold. Co-administration of fluconazole increased ivacaftor AUC by 2.9-fold. The dose of Trikafta should be reduced when co-administered with moderate CYP3A inhibitors (see «Warnings and precautions» and Table 3 in «Dosage/Administration»).

Examples of moderate CYP3A inhibitors include:

- fluconazole
- erythromycin

Co-administration of Trikafta with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure of elexacaftor, tezacaftor and ivacaftor. Food or drink containing grapefruit should be avoided during treatment with Trikafta (see «Dosage/Administration»).

The effects of co-administered drugs on the exposure of elexacaftor, tezacaftor and/or ivacaftor are shown in Table 4.

Table 4: Impact of Other Drugs on Elexacaftor, Tezacaftor and/or Ivacaftor

Dose and Schedule		Effect on ELX, TEZ and/or IVA PK	Geometric Mean Ratio (90% CI) of Elexacaftor, Tezacaftor and Ivacaftor No Effect = 1.0	
			AUC	C_{max}
Itraconazole 200 mg q12h on Day 1, followed by 200 mg qd	TEZ 25 mg qd + IVA 50 mg qd	↑ Tezacaftor	4.02 (3.71, 4.63)	2.83 (2.62, 3.07)
		↑ Ivacaftor	15.6 (13.4, 18.1)	8.60 (7.41, 9.98)
Itraconazole 200 mg qd	ELX 20 mg + TEZ 50 mg single dose	↑ Elexacaftor	2.83 (2.59, 3.10)	1.05 (0.977, 1.13)
		↑ Tezacaftor	4.51 (3.85, 5.29)	1.48 (1.33, 1.65)
Ketoconazole 400 mg qd	IVA 150 mg single dose	↑ Ivacaftor	8.45 (7.14, 10.0)	2.65 (2.21, 3.18)
Ciprofloxacin 750 mg q12h	TEZ 50 mg q12h + IVA 150 mg q12h	↔ Tezacaftor	1.08 (1.03, 1.13)	1.05 (0.99, 1.11)
		↑ Ivacaftor*	1.17 (1.06, 1.30)	1.18 (1.06, 1.31)
Rifampin 600 mg qd	IVA 150 mg single dose	↓ Ivacaftor	0.114 (0.097, 0.136)	0.200 (0.168, 0.239)
Fluconazole 400 mg single dose on Day 1, followed by 200 mg qd	IVA 150 mg q12h	↑ Ivacaftor	2.95 (2.27, 3.82)	2.47 (1.93, 3.17)

↑ = increase, ↓ = decrease, ↔ = no change. CI = Confidence interval; ELX= elexacaftor; TEZ = tezacaftor; IVA = ivacaftor; PK = Pharmacokinetics

* Effect is not clinically significant

Medicinal products affected by Trikafta

CYP2C9 substrates

Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during co-administration of Trikafta with warfarin is recommended. Other medicinal products for which exposure may be increased by Trikafta include glimepiride and glipizide; these medicinal products should be used with caution.

Potential for interaction with transporters

Co-administration of ivacaftor or tezacaftor/ivacaftor with digoxin, a sensitive P-glycoprotein (P-gp) substrate, increased digoxin AUC by 1.3-fold, consistent with weak inhibition of P-gp by ivacaftor. Administration of Trikafta may increase systemic exposure of medicinal products that are sensitive substrates of P-gp, which may increase or prolong their therapeutic effect and adverse reactions. When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index

such as cyclosporine, everolimus, sirolimus, and tacrolimus, caution and appropriate monitoring should be used.

Elexacaftor and M23-ELX inhibit uptake by OATP1B1 and OATP1B3 *in vitro*. Tezacaftor/ivacaftor increased the AUC of pitavastatin, an OATP1B1 substrate, by 1.2-fold. Co-administration of Trikafta may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. When used concomitantly with substrates of OATP1B1 or OATP1B3, caution and appropriate monitoring should be used. Bilirubin is an OATP1B1 and OATP1B3 substrate. In Study 445-102, mild increases in mean total bilirubin were observed (up to 4.0 µmol/L change from baseline). This finding is consistent with the *in vitro* inhibition of bilirubin transporters OATP1B1 and OATP1B3 by elexacaftor and M23-ELX.

Hormonal contraceptives

Trikafta has been studied with ethinyl estradiol/levonorgestrel and was found to have no clinically relevant effect on the exposures of the oral contraceptive. Trikafta is not expected to have an impact on the efficacy of oral contraceptives.

The effects of elexacaftor, tezacaftor and/or ivacaftor on the exposure of co-administered drugs are shown in Table 5.

Table 5: Impact of Elexacaftor, Tezacaftor and/or Ivacaftor on Other Drugs

Dose and Schedule		**Effect on Other Drug PK**	**Geometric Mean Ratio (90% CI) of Other Drug No Effect=1.0**	
			AUC	**C_{max}**
Midazolam 2 mg single oral dose	TEZ 100 mg qd/IVA 150 mg q12h	↔ Midazolam	1.12 (1.01, 1.25)	1.13 (1.01, 1.25)
Digoxin 0.5 mg single dose	TEZ 100 mg qd/IVA 150 mg q12h	↑ Digoxin	1.30 (1.17, 1.45)	1.32 (1.07, 1.64)
Oral Contraceptive Ethinyl estradiol 30 µg/Levonorgestrel 150 µg qd	ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h	↑ Ethinyl estradiol* ↑ Levonorgestrel*	1.33 (1.20, 1.49) 1.23 (1.10, 1.37)	1.26 (1.14, 1.39) 1.10 (0.985, 1.23)
Rosiglitazone 4 mg single oral dose	IVA 150 mg q12h	↔ Rosiglitazone	0.975 (0.897, 1.06)	0.928 (0.858, 1.00)
Desipramine 50 mg single dose	IVA 150 mg q12h	↔ Desipramine	1.04 (0.985, 1.10)	1.00 (0.939; 1.07)

↑ = increase, ↓ = decrease, ↔ = no change. CI = Confidence interval; ELX= elexacaftor;

TEZ = tezacaftor; IVA = ivacaftor; PK = Pharmacokinetics

* Effect not clinically significant.

Pregnancy, lactation

Pregnancy

No adequate and well-controlled studies of Trikafta in pregnant women have been conducted. Animal studies with the individual active substances did not show any direct toxicity in terms of pregnancy,

embryofetal development or postnatal development (see «Preclinical Data»). As a precautionary measure, use of the therapy should be avoided during pregnancy.

Lactation

It is not known whether elexacaftor, tezacaftor, ivacaftor or their metabolites are excreted into human breast milk. Available pharmacokinetic data in animals have shown excretion of elexacaftor, tezacaftor, and ivacaftor into the milk of lactating female rats. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy with Trikafta taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

There are no data available on the effect of elexacaftor, tezacaftor, and ivacaftor on fertility in humans. In animal studies, elexacaftor and ivacaftor had an effect on the fertility of rats. In animal studies, tezacaftor showed no effect on mating behaviour and fertility parameters(see «Preclinical data»).

Effects on ability to drive and use machines

The influence of Trikafta on the ability to drive and use machines has not been specifically investigated.

Undesirable effects

Summary of the safety profile

The safety profile of Trikafta is based on data from 510 patients in two double-blind, controlled, phase 3 studies of 24 weeks and 4 weeks treatment duration (Studies 445-102 and 445-103). In the two controlled phase 3 studies, a total of 257 patients aged 12 years and older received at least one dose of Trikafta.
In Study 445-102, the proportion of patients who discontinued study drug prematurely due to adverse events was 1% for Trikafta-treated patients and 0% for placebo-treated patients.
Serious adverse drug reactions that occurred more frequently in Trikafta-treated patients compared to placebo were rash events in 3 (1.5%) Trikafta-treated patients vs.1 (0.5%) placebo. The most common (⩾10%) adverse drug reactions in patients treated with Trikafta were headache (17.3%), diarrhea (12.9%) and upper respiratory tract infection (11.9%).
The safety profile of Trikafta was generally similar across all subgroups of patients, including analysis by age, sex, baseline percent predicted FEV_1 ($ppFEV_1$), and geographic regions.

Tabulated list of adverse reactions

Table 6 reflects adverse reactions observed with elexacaftor/tezacaftor/ivacaftor in combination with ivacaftor, tezacaftor/ivacaftor in combination with ivacaftor and ivacaftor. Adverse drug reactions for

Trikafta are ranked under the MedDRA frequency classification: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

Table 6: Adverse reactions during use of elexacaftor/tezacaftor/ivacaftor, tezacaftor/ivacaftor and ivacaftor alone in adolescents >12 years and adults		
MedDRA System Organ Class	**Adverse Reactions**	**Frequency**
Infections and infestations	Upper respiratory tract infection*, Nasopharyngitis	very common
	Rhinitis*, Influenza*	common
Metabolism and nutrition disorders	Hypoglycaemia*	common
Nervous system disorders	Headache*, Dizziness*	very common
Ear and labyrinth disorders	Ear pain, Ear discomfort, Tinnitus, Tympanic membrane hyperaemia, Vestibular disorder	common
	Ear congestion	uncommon
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain, Nasal congestion*	very common
	Rhinorrhoea*, Sinus congestion, Pharyngeal erythema, Abnormal breathing*	common
	Wheezing*	uncommon
Gastrointestinal disorders	Diarrhoea*, Abdominal pain*	very common
	Nausea, Abdominal pain upper*, Flatulence*	common
Hepatobiliary disorders	Transaminase elevations	very common
	Alanine aminotransferase increased*, Aspartate aminotransferase increased*	common
Skin and subcutaneous tissue disorders	Rash*	very common
	Acne*, Pruritus*	common
Reproductive system and breast disorders	Breast mass	common
	Breast inflammation, Gynaecomastia, Nipple disorder, Nipple pain	uncommon
Investigations	Bacteria in sputum	very common
	Blood creatine phosphokinase increased*	common
	Blood pressure increased*	uncommon
*Adverse reactions observed during clinical studies with elexacaftor/tezacaftor/ivacaftor in combination with ivacaftor.		

Safety data from the following studies in adolescents >12 years and adults were consistent with the safety data observed in Study 445-102.

- A 4-week, randomized, double-blind, active-controlled study in 107 patients (Study 445-103).
- A 96-week, open-label safety and efficacy study (Study 445-105) for patients rolled over from Studies 445-102 and 445-103, with interim analysis performed on 509 patients including 58 patients with ≥48 weeks of cumulative treatment with Trikafta.

- An 8-week, randomized, double-blind, active-controlled study in 258 patients (Study 445-104).

A 24-week, open-label study examined 66 patients aged 6 to less than 12 years (Study 445-106 part B). See below for details on liver and skin adverse events.

Description of selected undesirable effects

Transaminase elevations

In Study 445-102, the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 x the ULN was 1.5%, 2.5%, and 7.9% in Trikafta-treated patients and 1.0%, 1.5%, and 5.5% in placebo-treated patients. The incidence of adverse reactions of transaminase elevations was 10.9% in Trikafta-treated patients and 4.0% in placebo-treated patients. No Trikafta-treated patients discontinued treatment for elevated transaminases.
During Study 445-106 part B in 66 patients aged 6 to less than 12 years, the incidence of maximum transaminase (ALT or AST) >8, >5, and >3 x ULN was 0%, 1.5%, and 10.6%, respectively. No Trikafta-treated patients had transaminase elevation >3 x ULN associated with elevated total bilirubin >2 x ULN or discontinued treatment due to transaminase elevations. For the adverse events of elevated transaminases the mean (SD) time to first event was 52.1 (62.2) days and the mean (SD) duration was 15.3 (9.0) days (see «Warnings and precautions»).

Rash Events

In Study 445-102, the incidence of rash events (e.g., rash, rash pruritic) was 10.9% in Trikafta- and 6.5% in placebo-treated patients. The rash events were generally mild to moderate in severity. The incidence of rash events by patient sex was 5.8% in males and 16.3% in females in Trikafta-treated patients and 4.8% in males and 8.3% in females in placebo-treated patients.
A role for hormonal contraceptives in the occurrence of rash cannot be excluded. For patients taking hormonal contraceptives who develop rash, consider interrupting Trikafta and hormonal contraceptives. Following the resolution of rash, consider resuming Trikafta without the hormonal contraceptives. If rash does not recur, resumption of hormonal contraceptives can be considered.
In the Study 445-106 part B in 66 Trikafta-treated patients aged 6 to less than 12 years, the incidence of rash (e.g., rash, pruritic rash) was 24.2% (n=16). The specific adverse events included skin rash n=8 (12.1%), erythematous rash n=3 (4.5%), maculo-papular rash n=2 (3.0%), papular rash n=2 (3.0%), skin exfoliation n=1 (1.5%), urticaria n=1 (1.5%). One patient (1.5%) had a rash that led to discontinuation of Trikafta. The remaining patients had rash events that resolved with continued Trikafta treatment.

Increased Creatine Phosphokinase

In Study 445-102, the incidence of maximum creatine phosphokinase >5 x the ULN was 10.4% in Trikafta- and 5.0% in placebo-treated patients. No Trikafta-treated patients discontinued treatment for increased creatine phosphokinase.

Increased Blood Pressure

In Study 445-102, the maximum increase from baseline in mean systolic and diastolic blood pressure was 3.5 mmHg and 1.9 mmHg, respectively for Trikafta-treated patients (baseline: 113 mmHg systolic and 69 mmHg diastolic) and 0.9 mmHg and 0.5 mmHg, respectively for placebo-treated patients (baseline: 114 mmHg systolic and 70 mmHg diastolic).
The proportion of patients who had systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg on at least two occasions was 5.0% and 3.0% in Trikafta-treated patients respectively, compared with 3.5% and 3.5% in placebo-treated patients, respectively.

Reporting suspected adverse reactions after authorisation of the medicinal product is very important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions online via the ElViS portal (Electronic Vigilance System). You can obtain information about this at www.swissmedic.ch.

Overdose

Treatment

No specific antidote is available for overdose with Trikafta. Treatment of overdose consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient.

Properties/Effects

ATC code

R07AX32

Mechanism of action

Elexacaftor and tezacaftor are CFTR correctors that bind to different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of F508del-CFTR to increase the amount of CFTR protein delivered to the cell surface compared to either molecule alone. Ivacaftor potentiates the channel open probability (or gating) of the CFTR protein at the cell surface. The combined effect of elexacaftor, tezacaftor and ivacaftor is increased quantity and function of F508del-CFTR at the cell surface, resulting in increased CFTR activity as measured by CFTR mediated chloride transport. Clinical outcomes were consistent with *in vitro* results and indicate that a single *F508del* mutation is sufficient to result in a significant clinical response (see «Clinical efficacy»).

Pharmacodynamics

Pharmacodynamic effects

Effects on sweat chloride

In Study 445-102 (patients with an *F508del* mutation on one allele and a mutation on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor [minimal function mutation]), a reduction in sweat chloride was observed from baseline at Week 4 and sustained through the 24-week treatment period. The treatment difference of Trikafta compared to placebo for mean absolute change in sweat chloride from baseline through Week 24 was -41.8 mmol/L (95% CI: -44.4, -39.3; *P*<0.0001).
In Study 445-103 (patients homozygous for the *F508del* mutation), the treatment difference of Trikafta compared to the tezacaftor/ivacaftor and ivacaftor regimen (tezacaftor/ivacaftor) for mean absolute change in sweat chloride from baseline at Week 4 was -45.1 mmol/L (95% CI: -50.1, -40.1, *P*<0.0001).
In Study 445-104 (patients heterozygous for the *F508del* mutation and a gating or residual function mutation on the second allele), following a 4-week ivacafor or tezacaftor/ivacaftor run-in period, the mean absolute change in sweat chloride from baseline through Week 8 for the Trikafta group was -22.3 mmol/L (95% CI: -24.5, -20.2; *P*<0.0001). The treatment difference of Trikafta compared to the control group (ivacaftor or tezacaftor/ivacaftor) was -23.1 mmol/L (95% CI: -26.1, -20.1; *P*<0.0001).
In Study 445-106 (patients aged 6 to less than 12 years who are homozygous for the *F508del* mutation or heterozygous for the *F508del* mutation and a minimal function mutation), the mean absolute change in sweat chloride from baseline through Week 24 was -60.9 mmol/L (95% CI: -63.7, -58.2). The measured values for the sweat chloride concentration were collected on the planned measurement days in the following number of patients: baseline n=62, day 15 n=56, week 4 n=56, week 12 n=50, week 24 n=28.

Cardiovascular Effects

Effect on QT interval

At doses up to 2 times the maximum recommended dose of elexacaftor and 3 times the maximum recommended dose of tezacaftor and ivacaftor, the QT/QTc interval in healthy subjects was not prolonged to any clinically relevant extent.

Heart Rate

In Study 445-102, mean decreases in heart rate of 3.7 to 5.8 beats per minute (bpm) from baseline (76 bpm) were observed in Trikafta-treated patients.

Clinical efficacy

The efficacy of Trikafta in patients with CF was statistically demonstrated in three Phase 3 double blind, controlled studies (Studies 445-102, 445-103 and 445-104). These studies each enrolled CF patients who had at least one *F508del* mutation. Both open-label, uncontrolled phase 3 studies (Study 445-105 and Study 445-106 part B) provide additional support for efficacy. Trikafta was developed as a combination therapy containing elexacaftor, tezacaftor, and ivacaftor. The benefit of elexacaftor alone and tezacaftor alone in comparison with the combination therapy has not been investigated in clinical studies, and these active substances are not individually available as medicinal products.
Study 445-102 was a 24-week, randomized, double-blind, placebo-controlled study in patients who had an *F508del* mutation on one allele and a minimal function (MF) mutation on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor. A total of 403 patients aged 12 years and older (mean age 26.2 years) were randomized and dosed to receive Trikafta or placebo. Patients had a $ppFEV_1$ at screening between 40-90%. The mean $ppFEV_1$ at baseline was 61.4% (range: 32.3%, 97.1%).
Study 445-103 was a 4-week, randomized, double-blind, active-controlled study in patients who are homozygous for the *F508del* mutation. A total of 107 patients aged 12 years and older (mean age 28.4 years) received tezacaftor/ivacaftor and ivacaftor regimen (tezacaftor/ivacaftor) during a 4-week open-label run-in period and were then randomized and dosed to receive Trikafta or tezacaftor/ivacaftor during a 4-week double-blind treatment period. Patients had a $ppFEV_1$ at screening between 40-90%. The mean $ppFEV_1$ at baseline, following the tezacaftor/ivacaftor run-in period was 60.9% (range: 35.0%, 89.0%).
Study 445-104 was an 8-week, randomized, double-blind, active-controlled study in patients who were heterozygous for the *F508del* (F) mutation and a gating (G) or residual function (RF) mutation on the second allele. Patients aged 12 years and older with $ppFEV_1$ between 40-90% at screening received either ivacaftor (for F/G mutation patients) or tezacaftor/ivacaftor (for F/RF mutation patients) during a 4-week open-label run-in period. Patients with F/*R117H* genotype received ivacaftor during the run-in period. Patients were then randomized to the Trikafta group or remained on the CFTR modulator therapy received during the run-in period. The mean age at baseline, following the run-in period, was 37.7 years, and the mean $ppFEV_1$ at baseline was 67.6% (range: 29.7%, 113.5%).
Study 445-106 was a two-part 24-week open-label uncontrolled study in 66 patients aged 6 to less than 12 years (mean age at baseline 9.3 years) who were homozygous for the *F508del* mutation or heterozygous for the *F508del* mutation and a minimal function mutation. Part A evaluated pharmacokinetics and preliminary safety, Part B evaluated safety, tolerability, efficacy and pharmacokinetics. Patients weighing <30 kg at baseline (36 patients, 54.5%) were administered two elexacaftor/tezacaftor/ivacaftor 50 mg/25 mg/37.5 mg tablets in the morning and one ivacaftor 75 mg tablet in the evening. Patients weighing ≥30 kg at baseline (30 patients, 45.5%) were administered two elexacaftor/tezacaftor/ivacaftor 100 mg/50 mg/75 mg tablets in the morning and one ivacaftor

150 mg tablet in the evening. Patients had a screening $ppFEV_1$ ≥40% [mean $ppFEV_1$ at baseline of 88.8% (range: 39.0%, 127.1%)] and weighed ≥15 kg (required inclusion criterion).
Patients in Studies 445-102, 445-103, and 445-104 continued on their CF therapies (e.g., bronchodilators, inhaled antibiotics, dornase alfa, and hypertonic saline), but discontinued any previous CFTR modulator therapies, except for study drugs. Patients had a confirmed diagnosis of CF and at least one *F508del* mutation.
Patients who had lung infection with organisms associated with a more rapid decline in pulmonary status, including but not limited to *Burkholderia cenocepacia*, *Burkholderia dolosa*, or *Mycobacterium abscessus*, or who had an abnormal liver function test at screening (ALT, AST, ALP, or GGT ≥3 x ULN, or total bilirubin ≥2 x ULN), were excluded. Patients in Studies 445-102 and 445-103 were eligible to roll over into the 96-week open-label extension study (Study 445-105). Patients in Studies 445-104 and 445-106 part B were eligible to roll over into separate open-label extension studies.

Study 445-102

In Study 445-102 the primary endpoint was mean absolute change in $ppFEV_1$ from baseline through Week 24. Treatment with Trikafta compared to placebo resulted in statistically significant improvement in $ppFEV_1$ of 14.3 percentage points (95% CI: 12.7, 15.8; P<0.0001) (Table 7). Mean improvement in $ppFEV_1$ was rapid in onset (Day 15) and sustained through the 24-week treatment period (Figure 1). Improvements in $ppFEV_1$ were observed regardless of age, baseline $ppFEV_1$, sex, and geographic region. A total of 18 patients receiving Trikafta had $ppFEV_1$ <40 at baseline. The safety and efficacy in this subgroup were comparable to those observed in the overall population. See Table 7 for a summary of primary and key secondary outcomes.

Table 7: Primary and Key Secondary Efficacy Analyses, Full Analysis Set (Study 445-102)			
Analysis	**Statistic**	**Placebo N=203**	**Trikafta N=200**
Primary efficacy analysis			
Absolute change in $ppFEV_1$ from baseline through Week 24 (percentage points)	Treatment difference (95% CI) *P* value Within-group change (SE)	NA NA -0.4 (0.5)	14.3 (12.7, 15.8) *P*<0.0001 13.9 (0.6)
Key secondary efficacy analyses			
Absolute change in $ppFEV_1$ from baseline at Week 4 (percentage points)	Treatment difference (95% CI) *P* value Within-group change (SE)	NA NA -0.2 (0.6)	13.7 (12.0, 15.3) *P*<0.0001 13.5 (0.6)
Number of pulmonary exacerbations from baseline through Week 24‡	Number of events (event rate per year††) Rate ratio (95% CI) *P* value	113 (0.98) NA NA	41 (0.37) 0.37 (0.25, 0.55) *P*<0.0001
Absolute change in sweat chloride from baseline through Week 24 (mmol/L)	Treatment difference (95% CI) *P* value Within-group change (SE)	NA NA -0.4 (0.9)	-41.8 (-44.4, -39.3) *P*<0.0001 -42.2 (0.9)
Absolute change in CFQ-R respiratory domain score from baseline through Week 24 (points)	Treatment difference (95% CI) *P* value Within-group change (SE)	NA NA -2.7 (1.0)	20.2 (17.5, 23.0) *P*<0.0001 17.5 (1.0)
Absolute change in BMI from baseline at Week 24 (kg/m^2)	Treatment difference (95% CI) *P* value Within-group change (SE)	NA NA 0.09 (0.07)	1.04 (0.85, 1.23) *P*<0.0001 1.13 (0.07)
Absolute change in sweat chloride from baseline at Week 4 (mmol/L)	Treatment difference (95% CI) *P* value Within-group change (SE)	NA NA 0.1 (1.0)	-41.2 (-44.0, -38.5) *P*<0.0001 -41.2 (1.0)
Absolute change in CFQ-R respiratory domain score from baseline at Week 4 (points)	Treatment difference (95% CI) *P* value Within-group change (SE)	NA NA -1.9 (1.1)	20.1 (16.9, 23.2) *P*<0.0001 18.1 (1.1)
$ppFEV_1$: percent predicted forced expiratory volume in 1 second; CI: confidence interval; SE: Standard Error; NA: not applicable; CFQ-R: Cystic Fibrosis Questionnaire-Revised; BMI: body mass index. ‡ A pulmonary exacerbation was defined as a change in antibiotic therapy (IV, inhaled, or oral) as a result of 4 or more of 12 pre-specified sino-pulmonary signs/symptoms. †† Estimated event rate per year was calculated based on 48 weeks per year.			

Figure 1: Absolute Change from Baseline in Percent Predicted FEV_1 at Each Visit in Study 445-102



SE: Standard Error

ELX/TEZ/IVA: elexacaftor/tezacaftor/ivacaftor

Study 445-103

In Study 445-103 the primary endpoint was mean absolute change in $ppFEV_1$ from baseline at Week 4 of the double-blind treatment period. Treatment with Trikafta compared to the regimen of tezacaftor/ivacaftor and ivacaftor (tezacaftor/ivacaftor) resulted in a statistically significant improvement in $ppFEV_1$ of 10.0 percentage points (95% CI: 7.4, 12.6; P<0.0001) (Table 8). Improvements in $ppFEV_1$ were observed regardless of age, sex, baseline $ppFEV_1$, and geographic region. See Table 8 for a summary of primary and key secondary outcomes.

Table 8: Primary and Key Secondary Efficacy Analyses, Full Analysis Set (Study 445-103)			
Analysis*	**Statistic**	**Tezacaftor/ Ivacaftor# N=52**	**Trikafta N=55**
Primary efficacy analysis			
Absolute change in $ppFEV_1$ from baseline at Week 4 (percentage points)	Treatment difference (95% CI) *P* value Within-group change (SE)	NA NA 0.4 (0.9)	10.0 (7.4, 12.6) *P*<0.0001 10.4 (0.9)
Key secondary efficacy analyses			
Absolute change in sweat chloride from baseline at Week 4 (mmol/L)	Treatment difference (95% CI) *P* value Within-group change (SE)	NA NA 1.7 (1.8)	-45.1 (-50.1, -40.1) *P*<0.0001 -43.4 (1.7)
Absolute change in CFQ-R respiratory domain score from baseline at Week 4 (points)	Treatment difference (95% CI) *P* value Within-group change (SE)	NA NA -1.4 (2.0)	17.4 (11.8, 23.0) *P*<0.0001 16.0 (2.0)
$ppFEV_1$: percent predicted forced expiratory volume in 1 second; CI: confidence interval; SE: Standard Error; NA: not applicable; CFQ-R: Cystic Fibrosis Questionnaire-Revised. * Baseline for primary and key secondary endpoints is defined as the end of the 4-week tezacaftor/ivacaftor and ivacaftor run-in period. # Regimen of tezacaftor/ivacaftor and ivacaftor			

Figure 2: Absolute Change from Baseline in Percent Predicted FEV_1 at Each Visit in Study 445-103

SE: Standard Error

TEZ/IVA: tezacaftor/ivacaftor

ELX/TEZ/IVA: elexacaftor/tezacaftor/ivacaftor

Study 445-105

An ongoing, 96-week open-label extension study to evaluate the safety and efficacy of long-term treatment with Trikafta is being conducted in patients who rolled over from Studies 445-102 and 445-103. For patients homozygous for the *F508del* mutation who rolled over from Study 445-103 (N=107), an interim efficacy analysis was conducted when they completed Week 24 visit of Study 445-105. Patients who received Trikafta in Study 445-103, and continued treatment in Study 445-105, continued to show values similar to those observed during the controlled study phase for ppFEV1, CFQ-R respiratory domain score, and sweat chloride, through 28 weeks of cumulative treatment (i.e., through week 24 in study 445-105). The outcomes of the annual pulmonary exacerbation event rate through 28 weeks of cumulative treatment (i.e., through week 24 in Study 445-105), and BMI and BMI-z score at 28 weeks of cumulative treatment (week 24 in Study 445-105), were similar to those seen in patients with the genotypes studied in Study 445-102.

Study 445-104

Following a 4-week ivacaftor or tezacaftor/ivacaftor run-in period, the primary endpoint of within-group mean absolute change in $ppFEV_1$ from baseline through Week 8 for the Trikafta group resulted in the course in a statistically significant improvement of 3.7 percentage points (95% CI: 2.8, 4.6; $P<0.0001$) (see Table 9). Mean improvement in $ppFEV_1$ was observed at the first assessment on Day 15. Overall improvements in $ppFEV_1$ were observed regardless of age, sex, baseline $ppFEV_1$, geographic region, and genotype groups (F/G or F/RF).

See Table 9 for a summary of primary and secondary outcomes in the overall trial population.

Table 9: Primary and secondary efficacy analyses, full analysis set (Study 445-104)			
Analysis*	**Statistics**	**Control group[#] N=126**	**Trikafta N=132**
Primary analysis			
Absolute change in $ppFEV_1$ from baseline through Week 8 (percentage points)	Within-group change (95% CI) *p* value	0.2 (-0.7, 1.1) NA	3.7 (2.8, 4.6) *p*<0.0001
Key and other secondary analyses			
Absolute change in sweat chloride from baseline through Week 8 (mmol/L)	Within-group change (95% CI) *p* value	0.7 (-1.4, 2.8) NA	-22.3 (-24.5, -20.2) *p*<0.0001
Absolute change in $ppFEV_1$ from baseline through Week 8 compared to the control group (percentage points)	Treatment difference (95% CI) *p* value	NA NA	3.5 (2.2, 4.7) *p*<0.0001
Absolute change in sweat chloride from baseline through Week 8 compared to the control group (mmol/L)	Treatment difference (95% CI) *p* value	NA NA	-23.1 (-26.1, -20.1) *p*<0.0001
Absolute change in CFQ-R respiratory domain score from baseline through Week 8 (points)[≠]	Within-group change (95% CI)	1.6 (-0.8, 4.1)	10.3 (8.0, 12.7)
Absolute change in CFQ-R respiratory domain score from baseline through Week 8 compared to the control group (points)[≠]	Treatment difference (95% CI)	NA	8.7 (5.3, 12.1)

$ppFEV_1$: percent predicted forced expiratory volume in 1 second; CI: confidence interval; NA: not applicable; CFQ-R: Cystic Fibrosis Questionnaire-Revised.

* Baseline for primary and secondary endpoints is defined as the end of the 4-week run-in period of ivacaftor or tezacaftor/ivacaftor.

[#] Ivacaftor group or tezacaftor/ivacaftor group.

[≠] CFQ-R outcomes were not controlled for multiplicity based on the hierarchical testing procedure

Study 445-106 part B

In Study 445-106 part B the primary endpoint of safety and tolerability was evaluated through 24 weeks. Secondary endpoints were evaluation of efficacy and pharmacokinetics including the

absolute change in $ppFEV_1$ (1st secondary endpoint) and the sweat chloride concentration (2nd secondary endpoint, see «Pharmacodynamics» section) from baseline at Week 24; and number of pulmonary exacerbations from baseline through Week 24. Due to the conduct of the study 445-106 part B during the COVID19 pandemic, not all measurements could be performed as originally planned. The secondary endpoint measurements were affected to varying degrees by measurements not being performed. Table 10 shows the most important secondary efficacy outcomes in the overall 24-week analysis.

Measurements of $ppFEV_1$ levels were obtained on the scheduled measurement days in the following number of patients: baseline n=62, day 15 n=51, week 4 n=52, week 8 n=51, week 12 n=43, week 16 n=29, week 24 n=15.

The measured values for the sweat chloride concentration were collected on the planned measurement days in the following number of patients: baseline n=62, day 15 n=56, week 4 n=56, week 12 n=50, week 24 n=28.

Table 10: Secondary efficacy analyses, full analysis set through 24 weeks (Study 445-106 part B)

Analysis	Within-group change (95% CI) for Trikafta N=66
Absolute change in $ppFEV_1$ from baseline through Week 24 (percentage points)	10.2 (7.9, 12.6)
Absolute change in sweat chloride from baseline through Week 24 (mmol/L)	-60.9 (-63.7, -58.2)
Number of pulmonary exacerbations through Week 24‡	4 (0.12) ††

CI: confidence interval; $ppFEV_1$: percent predicted forced expiratory volume in 1 second.
‡ A pulmonary exacerbation was defined as a change in antibiotic therapy (IV, inhaled, or oral) as a result of 4 or more of 12 pre-specified sino-pulmonary signs/symptoms.
†† Number of events and estimated event rate per year based on 48 weeks per year.

Pharmacokinetics

The pharmacokinetics of elexacaftor, tezacaftor and ivacaftor are similar between healthy adult subjects and patients with CF. The pharmacokinetic parameters for elexacaftor, tezacaftor and ivacaftor in patients with CF aged 12 years and older are shown in Table 11.

Table 11: Pharmacokinetic Parameters of Trikafta Components

	Elexacaftor	Tezacaftor	Ivacaftor
General Information			
AUC (SD), µg·h/mL[a]	162 (47.5)[b]	89.3 (23.2)[b]	11.7 (4.01)[c]
C_{max}, (SD), µg/mL[a]	9.2 (2.1)	7.7 (1.7)	1.2 (0.3)

Table 11: Pharmacokinetic Parameters of Trikafta Components			
	Elexacaftor	**Tezacaftor**	**Ivacaftor**
Time to Steady State, days	Within 7 days	Within 8 days	Within 3-5 days
Accumulation Ratio	2.2	2.07	2.4
Absorption			
Absolute Bioavailability	80%	Not determined	Not determined
Median T_{max} (range), hours	6 (4 to 12)	3 (2 to 4)	4 (3 to 6)
Effect of Food	AUC increases 1.9- to 2.5-fold (moderate-fat meal)	No clinically significant effect	Exposure increases 2.5- to 4-fold
Distribution			
Mean (SD) Apparent Volume of Distribution, L[d]	53.7 (17.7)	82.0 (22.3)	293 (89.8)
Protein Binding[e]	> 99%	approximately 99%	approximately 99%
Elimination			
Mean (SD) Effective Half-Life, hours[f]	27.4 (9.31)	25.1 (4.93)	15.0 (3.92)
Mean (SD) Apparent Clearance, L/hours	1.18 (0.29)	0.79 (0.10)	10.2 (3.13)
Metabolism			
Primary Pathway	CYP3A4/5	CYP3A4/5	CYP3A4/5
Active Metabolites	M23-ELX	M1-TEZ	M1-IVA
Metabolite Potency Relative to Parent	Similar	Similar	approximately 1/6th of parent
Excretion[g]			
Primary Pathway	• Feces: 87.3% (primarily as metabolites) • Urine: 0.23%	• Feces: 72% (unchanged or as M2-TEZ) • Urine: 14% (0.79% unchanged)	• Feces: 87.8% • Urine: 6.6%

[a] Based on elexacaftor 200 mg and tezacaftor 100 mg once daily/ivacaftor 150 mg every 12 hours at steady state in patients with CF aged 12 year and older.
[b] AUC_{0-24h}.
[c] AUC_{0-12h}.
[d] Elexacaftor, tezacaftor and ivacaftor do not partition preferentially into human red blood cells.
[e] Elexacaftor and tezacaftor bind primarily to albumin. Ivacaftor primarily bind to albumin, alpha 1-acid glycoprotein and human gamma-globulin.
[f] Mean (SD) terminal half-lives of elexacaftor, tezacaftor and ivacaftor are approximately 24.7 (4.87) hours, 60.3 (15.7) hours and 13.1 (2.98) hours, respectively.
[g] Following radiolabeled doses.

Absorption

See Table 11, Pharmacokinetic Parameters of Trikafta Components

Distribution

See Table 11, Pharmacokinetic Parameters of Trikafta Components

Metabolism

See Table 11, Pharmacokinetic Parameters of Trikafta Components

Elimination

See Table 11, Pharmacokinetic Parameters of Trikafta Components

Kinetics in specific patient groups

Hepatic impairment

Elexacaftor alone or in combination with tezacaftor and ivacaftor has not been studied in subjects with severe hepatic impairment (Child-Pugh Class C, score 10-15). Following multiple doses of elexacaftor, tezacaftor and ivacaftor for 10 days, subjects with moderately impaired hepatic function (Child-Pugh Class B, score 7 to 9) had 25% higher AUC and 12% higher C_{max} for elexacaftor, 73% higher AUC and 70% higher C_{max} for M23-elexacaftor, 36% higher AUC and 24% higher C_{max} for combined elexacaftor and M23-elexacaftor, 20% higher AUC but similar C_{max} for tezacaftor, and a 50% higher AUC and 10% higher C_{max} for ivacaftor compared with healthy subjects matched for demographics.

Tezacaftor and ivacaftor

Following multiple doses of tezacaftor and ivacaftor for 10 days, subjects with moderately impaired hepatic function had an approximately 36% higher AUC and a 10% higher C_{max} for tezacaftor, and a 1.5-fold higher AUC but similar C_{max} for ivacaftor compared with healthy subjects matched for demographics.

Ivacaftor

In a study with ivacaftor alone, subjects with moderately impaired hepatic function had similar ivacaftor C_{max}, but an approximately 2.0-fold higher ivacaftor $AUC_{0-\infty}$ compared with healthy subjects matched for demographics.

Renal impairment

Elexacaftor alone or in combination with tezacaftor and ivacaftor has not been studied in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m^2) or in patients with end stage renal disease.
In human pharmacokinetic studies of elexacaftor, tezacaftor, and ivacaftor, there was minimal elimination of elexacaftor, tezacaftor, and ivacaftor in urine (only 0.23%, 13.7% [0.79% as unchanged drug], and 6.6% of total radioactivity, respectively).
Based on population pharmacokinetic (PK) analysis, exposure of elexacaftor was similar in patients with mild renal impairment (N=75, eGFR 60 to less than 90 mL/min/1.73 m^2) relative to patients with normal renal function (N=341, eGFR 90 mL/min/1.73 m^2 or greater).

In population PK analysis conducted in 817 patients administered tezacaftor alone or in combination with ivacaftor in Phase 2 or Phase 3 studies indicated that mild renal impairment (N=172; eGFR 60 to less than 90 mL/min/1.73 m^2) and moderate renal impairment (N=8; eGFR 30 to less than 60 mL/min/1.73 m^2) did not affect the clearance of tezacaftor significantly.

Gender

Based on population PK analysis, the exposures of elexacaftor, tezacaftor and ivacaftor are similar in males and females.

Pediatric patients 6 to less than 18 years of age

Elexacaftor, tezacaftor and ivacaftor exposures, and the exposures of the M1-tezacaftor and M23-elexacaftor metabolites, observed in Phase 3 studies as determined using population PK analysis are presented by age group and dose administered in Table 12. Exposures of elexacaftor, tezacaftor and ivacaftor in patients aged 6 to less than 18 years of age are within the range observed in patients aged 18 years and older.

Table 12. Mean (SD) Elexacaftor, Tezacaftor and Ivacaftor Exposures by Age Group

Age group	Dose	Elexacaftor $AUC_{0\text{-}24h,ss}$ (µg·h/mL)	M23-Elexacaftor $AUC_{0\text{-}24h,ss}$ (µg·h/mL)	Tezacaftor $AUC_{0\text{-}24h,ss}$ (µg·h/mL)	M1-Tezacaftor $AUC_{0\text{-}24h,ss}$ (µg·h/mL)	Ivacaftor $AUC_{0\text{-}12h,ss}$ (µg·h/mL)
Patients aged 6 to <12 years weighing <30 kg (N=36)	elexacaftor 100 mg qd/tezacaftor 50 mg qd/ivacaftor 75 mg q12h	116 (39.4)	45.4 (25.2)	67.0 (22.3)	153 (36.5)	9.78 (4.50)
Patients aged 6 to <12 years weighing ≥30 kg (N=30)	elexacaftor 200 mg qd/tezacaftor 100 mg qd/ivacaftor 150 mg q12h	195 (59.4)	104 (52)	103 (23.7)	220 (37.5)	17.5 (4.97)
Adolescent patients (12 to <18 years) (N=72)	elexacaftor 200 mg qd/tezacaftor 100 mg qd/ivacaftor 150 mg q12h	147 (36.8)	58.5 (25.6)	88.8 (21.8)	148 (333)	10.6 (3.35)
Adult patients (≥18 years) (N=179)	elexacaftor 200 mg qd/tezacaftor 100 mg qd/ivacaftor 150 mg q12h	168 (49.9)	64.6 (28.9)	89.5 (23.7)	128 (33.7)	12.1 (4.17)

SD: Standard Deviation; AUC_{ss}: area under the concentration versus time curve at steady state.

Preclinical data

Elexacaftor/tezacaftor/ivacaftor

Repeated dose toxicity studies in rats and dogs in which elexacaftor, tezacaftor and ivacaftor were administered in combination to assess the potential for additive and/or synergistic toxicity did not result in unexpected toxicities or interactions. No safety pharmacology, genotoxicity, carcinogenicity or reproductive toxicity studies were performed with Trikafta. However, studies with the individual substances are available.

Elexacaftor

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and genotoxicity.

Repeat dose toxicity

In the 6-month rat toxicity study, the primary target organs were the glandular stomach (erosion), testes and epididymis (degeneration/atropy of the seminiferous tubules, oligospermia/aspermia), and bone marrow (decreased hematopoietic cellularity). These effects were primarily observed at non-tolerated doses of ≥40 mg/kg/day in male animals and 30 mg/kg/day in female animals. Plasma exposure (AUC) in animals at NOAEL (15 mg/kg/day) was approximately 3-fold (males) and 11-fold (females) the maximum recommended dose for humans [MRHD]. In the 9-month dog toxicity study, minimal or mild non-adverse bilateral degeneration/atrophy of the seminiferous tubules of the testes was present in males administered elexacaftor at 14 mg/kg/day dose (14 times the MRHD based on summed AUCs of elexacaftor and its metabolites) that did not resolve during the limited recovery period, however without further sequelae. The human relevance of these findings is unknown.

Reproduction toxicity

Elexacaftor was associated with lower male and female fertility, male copulation, and female conception indices in males at 75 mg/kg/day (6 times the MRHD based on summed AUCs of elexacaftor and its metabolite) and in females at 35 mg/kg/day (7 times the MRHD based on summed AUCs of elexacaftor and its metabolite).
Elexacaftor was not teratogenic in rats at 40 mg/kg/day and at 125 mg/kg/day in rabbits (approximately 9 and 4 times, respectively, the MRHD based on summed AUCs of elexacaftor and its metabolites [for rat] and AUC of elexacaftor [for rabbit]). In rat fetuses a lower mean body weight was observed after treatment of the mother animals with ≥ 25 mg/kg/day (approximately 4 times the MRHD based on AUC). No adverse effects were noted in the rat pre- and post-natal development study with doses of up to 10 mg/kg/day (around 1-fold the MRHD based on the summed AUCs of elexacaftor and its metabolites). Placental transfer of elexacaftor was observed in pregnant rats.

Juvenile toxicity

No adverse effects were noted in juvenile rats dosed from postnatal Day 7 through Day 70 with doses that led to plasma exposure of approx. 3-fold (males) and 5-fold (females) the AUC in paediatric patients (aged 12 years and older).

Carcinogenicity

Elexacaftor was shown to be non-carcinogenic in a 6 month study in Tg.rasH2 mice.

Tezacaftor

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity, carcinogenic potential and repeated dose toxicity.

Reproductive toxicity

Tezacaftor did not cause reproductive system toxicity in male and female rats at 100 mg/kg/day, the highest dose evaluated (approximately 3 times the MRHD based on summed AUCs of tezacaftor and M1 TEZ).
Tezacaftor had no effect on the fertility and reproductive performance indices of male and female rats at doses up to 100 mg/kg/day (approximately 3 times the MRHD based on the summed AUCs of tezacaftor and M1 TEZ).
Tezacaftor was not teratogenic in pregnant rats and rabbits at doses approximately 3 times and 0.2 times, respectively, the tezacaftor exposure in humans at the therapeutic dose.
In a pre-and post-natal development study, tezacaftor did not cause developmental defects in the offspring of pregnant rats dosed orally at 25 mg/kg/day (approximately 1 time the MRHD based on summed AUCs for tezacaftor and M1 TEZ). At maternally toxic doses (≥50 mg/kg/day), tezacaftor produced lower foetal body weights, a lower fertility index, and effects on estrous cyclicity (increased cycle length and decrease in number of cycles). At the highest dose (100 mg/kg/day), tezacaftor related effects in offspring included poor pup survival to weaning, preweaning developmental effects, and sexual maturation delays. Placental transfer of tezacaftor was observed in pregnant rats.

Ivacaftor

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity, carcinogenic potential, and repeated dose toxicity.

Reproductive toxicity

Ivacaftor affected the fertility and reproductive performance indices of male and female rats at doses of 200 mg/kg/day (approximately 7 and 5 times the MRHD, respectively, based on the summed AUCs of ivacaftor and its metabolites. Among the female animals ivacaftor was associated with a reduction in overall fertility index, number of pregnancies, number of corpora lutea and implantation sites, as well as changes in the estrous cycle. Ivacaftor also increased the number of females in which all

embryos were not viable and reduced the number of viable embryos. Slight decreases of the seminal vesicle weights were observed in males. These impairments of fertility and reproductive performance were attributed to severe toxicity in rats under a dose of 200 mg/kg/day. No effects on male or female fertility and reproductive performance indices were observed after doses of ≤ 100 mg/kg/day (approximately 5-fold and 3-fold, respectively, the MRHD based on the summed AUCs of ivacaftor and its metabolites). Ivacaftor was not teratogenic in rats after 200 mg/kg/day and in rabbits after 100 mg/kg/day (approximately 6 and 16 times the MRHD, respectively, based on the sum of AUCs of ivacaftor and its metabolites). Effects on fetal body weight and slight increases in common variations in skeletal development were found in rats at doses that were associated with significant toxicity in the dam.
In pre- and post-natal development study in pregnant rats at doses above 100 mg/kg/day, ivacaftor resulted in survival and lactation indices that were 92% and 98% of control values, respectively, as well as reductions in pup body weights. Placental transfer of ivacaftor was observed in pregnant rats and rabbits.

Juvenile toxicity

Findings of cataracts were observed in juvenile rats dosed from postnatal Day 7 through 35 with ivacaftor dose levels of 10 mg/kg/day and higher (0.2 times the MRHD based on systemic exposure of ivacaftor and its metabolites). This finding has not been observed in fetuses derived from rat dams treated with ivacaftor on gestation Days 7 to 17, in rat pups exposed to ivacaftor to a certain extent through milk ingestion up to postnatal Day 20, in 7-week-old rats, or in 3.5- to 5-month-old dogs treated with ivacaftor. The potential relevance of these findings in humans is unknown.

Other information

Shelf life

Do not use this medicine after the expiry date («EXP») stated on the container.

Special precautions for storage

Do not store above 30°C.
Keep out of the sight and reach of children.

Authorisation number

67773 (Swissmedic)

Packs

Trikafta film-coated tablets

- Elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg tablet and ivacaftor 75 mg tablet
  - Pack size of 84 tablets (4 weekly wallets, each with 14 elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg film-coated tablets and with 7 ivacaftor 75 mg film-coated tablets). [A]

- Elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg tablet and ivacaftor 150 mg tablet
  - Pack size of 84 tablets (4 weekly wallets, each with 14 elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg film-coated tablets and with 7 ivacaftor 150 mg film-coated tablets). [A]

Marketing authorisation holder

Vertex Pharmaceuticals (CH) GmbH
6300 Zug

Date of revision of the text

October 2021